<DOC>
	<DOC>NCT01913431</DOC>
	<brief_summary>This is a multicenter, double blind, active-controlled, randomized, parallel group study to demonstrate the anti-viral activity and safety of Baracle Tab. and Baraclude Tab. for patients with HBeAg Chronic Hepatitis B. The subject will receive two tablets daily for 48 days.</brief_summary>
	<brief_title>Baracle Tab. ® Versus Baraclude Tab.® for Patients With HBeAg Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>Subjects with HbeAg Chronic Hepatitis B for at least six months starting from the Screening visit Subjects with HBsAgPositive diagnosed at the screening visit Subjects with HBeAgPositive or HBeAgnegative diagnosed at the screening visit For those who were diagnosed HBeAgPositive, HBV DNA level should be equal or more than 1x10^5 copies/ml For those who were diagnosed HBeAgNegative, HBV DNA level should be equal or more than 1x10^5 copies/ml Subjects who were NOT administrated any antiviral agents including interferon or pegylated interferon Subjects with HCV, HDV or HIV Subjects with decompensated liver disease who have more than 2.5mg/dl of total bilirubin, longer than 3 seconds of prothrombin time, less than 30g/l of serum albumin With medical history of hemorrhage, hepatic encephalopathy, or dyshepatia due to ascites, jaundice, varicose vein Less than 50ml/min of creatinine clearance diagnosed at the screening visit More than 50 ng/ml of alphafetoprotein at the screening visit Involved in other studies</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>